Allarity Therapeutics

What Allarity Therapeutics does

Allarity Therapeutics is a clinical-stage precision medicine biopharmaceutical company developing personalized oncology therapeutics, with its lead and now sole focus being stenoparib, an orally bioavailable small-molecule dual inhibitor of PARP1/2 and tankyrase 1/2 (WNT pathway). Originally developed by Eisai (formerly E7449 / 2X-121), stenoparib is being advanced under exclusive global rights held by Allarity for advanced platinum-resistant and platinum-ineligible ovarian cancer and, more recently, relapsed small cell lung cancer. The company has FDA Fast Track designation for the ovarian cancer indication (August 2025) and reported Phase 2 median overall survival exceeding 25 months, with some patients on therapy for more than 30 months.

The company's technical backbone is the proprietary Drug Response Predictor (DRP) platform, a first-in-class diagnostic that models tumor biology from gene expression data (a 414-mRNA signature) drawn from more than 3,000 patient tumors and validated across dozens of clinical studies. The DRP-Stenoparib companion diagnostic (CDx) is intended to pair with the drug for patient selection. The DRP platform has also been extended to antibody therapies (e.g., a DRP for daratumumab in multiple myeloma) and licensed externally (e.g., a 2025 breast cancer algorithm license to an EU biotech partner), supporting an additional services and licensing revenue stream through Allarity's wholly owned medical laboratory in Horsholm, Denmark. Allarity holds 18 granted patents for drug-specific DRPs and has a USPTO Notice of Allowance expected to extend stenoparib exclusivity by at least 11 years.

Commercially, Allarity is pre-revenue and pre-commercial; it generates only nominal DRP laboratory services and licensing income and funds operations primarily through capital markets and debt. Operations are run with 1-10 employees across a US headquarters in Tarpon Springs, Florida, and an R&D / medical laboratory in Denmark. The 2024 strategic reset narrowed the portfolio to stenoparib alone, restored Nasdaq compliance, and simplified the capital structure. The company has since added Phase 2 data, FDA Fast Track designation, a $20M debt facility from Streeterville Capital extending runway into mid-2028, a VA-funded Phase 2 combination trial in small cell lung cancer across 11 VA medical centers, and a Phase 3-ready Lonza GMP manufacturing campaign on track for Q3 2026. Lonza manufactures the clinical and prospective commercial supply; Eisai is the originator; the U.S. Department of Veterans Affairs is funding the SCLC trial.

Name

Allarity Therapeutics

Legal name

Allarity Therapeutics, Inc.

Website

https://allarity.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

Allarity Therapeutics is a clinical-stage precision oncology biopharmaceutical company developing stenoparib, a dual PARP/tankyrase inhibitor, paired with its proprietary DRP companion diagnostic platform for personalized cancer treatment selection. The company targets advanced ovarian cancer and relapsed small cell lung cancer and trades on NASDAQ as ALLR.

Ownership category

akta.pro rank

Product category

Precision Oncology Pharmaceuticals

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)

akta.pro primary industry

Predictive Biomarkers for Therapy Selection (response/non-response stratification) (HLAAAMAE)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Precision oncology therapeutics
• Companion diagnostics
• Drug response prediction
• PARP inhibitors
• Clinical stage biopharmaceuticals

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Commercialization: Revenue will be generated through the commercialization of stenoparib and potentially other drug candidates upon regulatory approval. The company holds exclusive global rights for stenoparib development and commercialization.
2. Laboratory Services and DRP Testing: Revenue generated from supplying transcriptome analysis services through Allarity's Medical Laboratory in Denmark. Services support partners' precision oncology efforts. Purchase commitments secured through licensing agreements.
3. DRP Platform Licensing: Non-exclusive global licenses to proprietary DRP algorithms granted to external biotechnology and pharmaceutical companies for use in their drug development programs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Allarity Therapeutics is a clinical-stage precision medicine company developing stenoparib, an orally available small-molecule dual inhibitor of PARP1/2 and tankyrase 1/2, for advanced ovarian cancer and small cell lung cancer. The company pairs stenoparib with its proprietary Drug Response Predictor (DRP) companion diagnostic platform, which uses a 414-mRNA gene expression signature from patient tumor biopsies to identify patients most likely to benefit from specific therapies.

Product overview

Allarity Therapeutics is a clinical-stage precision medicine company offering a portfolio centered on stenoparib, its lead drug candidate (a dual PARP and WNT pathway inhibitor), paired with the proprietary DRP companion diagnostic platform. The portfolio consists of: stenoparib as the core therapeutic product; the DRP Stenoparib companion diagnostic (CDx) that uses a 414-mRNA gene expression signature to select patients most likely to benefit; the broader DRP Technology Platform that can be applied across multiple cancer types and drug classes; DRP Cancer Tests as laboratory services; Allarity Medical Laboratory services for transcriptome analysis; and DRP Software tools. The DRP platform is licensed to external partners (e.g., EU biotech for breast cancer algorithms) while also supporting internal drug development. The company also partners with Lonza for GMP drug manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• DRP (Drug Response Predictor): Proprietary first-in-class diagnostic platform that models human tumor biology to predict patient response to specific drugs
• DRP Cancer Tests
• Stenoparib

Products and services

• Stenoparib

Quantifiable outcome

• Median overall survival exceeding 25 months in advanced platinum-resistant ovarian cancer patients (vs. approximately 16-16.5 months for recent FDA-approved therapies)
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and secondary.

• U.S. Department of Veterans Affairs (VA)coreStrategic or Co-development Partner · 18 February 2026VA-funded Phase 2 clinical trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer, fully funded through the VA's Special Emphasis Panel on Precision Oncology. Trial conducted across 11 VA medical centers nationwide. Principal Investigator: Dr. Shadia Jalal, Indiana University.
• Lawrence H. Einhorn Chair in Oncology at Indiana UniversitysecondaryStrategic or Co-development Partner · 3 February 2026Principal Investigator Dr. Shadia Jalal serves as Professor of Medicine at the Lawrence H. Einhorn Chair in Oncology at Indiana University's Melvin and Bren Comprehensive Cancer Center for the VA-funded SCLC trial.
• Indiana Biosciences Research Institute (IBRI)secondaryStrategic or Co-development Partner · 15 August 2025Research collaboration to conduct advanced molecular and cellular studies clarifying the individual and combined contributions of PARP inhibition and WNT pathway modulation to stenoparib's anti-cancer effects. Aims to deepen mechanistic understanding and potentially expand therapeutic opportunities including in colorectal cancer.
• EU-based biotechnology company (Non-disclosed)secondaryTechnology or Integration · 15 July 2025Non-exclusive global license to a range of selected proprietary DRP algorithms in breast cancer, alongside laboratory services from Allarity's Medical Laboratory in Denmark. Deal secures purchase commitments for laboratory services over the next year.
• LonzacoreStrategic or Co-development PartnerPartnership with Lonza for GMP drug manufacturing to meet the strictest regulatory requirements worldwide for stenoparib production. Phase 3-ready active pharmaceutical ingredient manufacturing campaign on track for completion in Q3 2026.
• Eisai Co. Ltd.coreStrategic or Co-development PartnerAllarity holds exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. (formerly known as E7449 and 2X-121).

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Clovis Oncology: Developer of Rubraca (rucaparib), a PARP inhibitor approved for ovarian and prostate cancers. Direct comparator to stenoparib given similar indication focus and mechanism, though facing commercial and financial challenges that highlight the difficulty of competing with established PARP inhibitors as a smaller player.
• Myriad Genetics: Provider of BRACAnalysis CDx and other molecular companion diagnostics used to guide PARP inhibitor therapy selection. Closest direct peer to Allarity's DRP companion diagnostic concept, though Myriad's tests are primarily germline BRCA-focused versus Allarity's broader transcriptomic DRP signatures.
• Caris Life Sciences: Molecular profiling company offering MI Profile and Caris Assure for therapy selection in oncology. Comparable as a precision oncology diagnostics provider leveraging multi-omic data to predict treatment response, similar in spirit to Allarity's DRP platform.

Emerging players

• Tempus AI: AI-enabled precision medicine company offering multi-modal molecular profiling, including transcriptomic and genomic tests, to guide oncology treatment selection. Overlaps with DRP's gene-expression-based response prediction but at much greater scale and broader diagnostic scope.
• Personalis: Molecular diagnostics company with a tumor profiling platform (ImmunoID NeXT) that integrates whole-transcriptome and genomic data for cancer therapy selection. Comparable to Allarity's DRP in using transcriptomic data for therapy guidance, though focused more on immunotherapy biomarkers.
• Natera: Molecular diagnostics company with Signatera (tumor-informed MRD) and Empower (germline testing) used in oncology decision-making. Comparable as a precision oncology diagnostic platform, though primarily focused on minimal residual disease rather than upfront therapy selection.

Broad incumbents

• AstraZeneca: Developer of Lynparza (olaparib), the leading first-generation PARP inhibitor approved across ovarian, breast, prostate, and pancreatic cancers. Sets the competitive benchmark for stenoparib's commercial opportunity and reimbursement environment in PARP-sensitive tumors.
• GSK: Markets Zejula (niraparib), a leading PARP inhibitor approved for first-line maintenance treatment of ovarian cancer. Represents one of the primary competitive threats and partnership candidates for stenoparib.
• Pfizer: Markets Talzenna (talazoparib) for breast and prostate cancers and has broader PARP-combination programs. Relevant incumbent competitor with established commercial reach in the same drug class.
• Foundation Medicine: Provider of FoundationOne CDx, a broad comprehensive genomic profiling companion diagnostic used to guide therapy selection across multiple cancer types, including PARP inhibitor eligibility. Largest established CDx player against which DRP would compete for diagnostic adoption.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/AllarityTx
• LinkedInlinkedin.com/company/allaritytx
• Facebookfacebook.com/AllarityTx

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allarity Therapeutics